# Journal of Nuclear Medicine

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/journal-of-nuclear-medicine/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 0161-5505 |
| ISSNs | 0161-5505,1535-5667,2159-662X |
| OpenAlex ID | https://openalex.org/S4210180780 |
| Publisher | Society of Nuclear Medicine and Molecular Imaging |

## Journal papers

Showing 12 of 31.

- [Multicenter Standardized <sup>18</sup>F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias](https://scholariq.org/papers/multicenter-standardized-sup-18-sup-f-fdg-pet-diagnosis-of-mild-cognitive/)
- [In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand <sup>18</sup>F-AV-45 (Flobetapir F 18)](https://scholariq.org/papers/in-vivo-imaging-of-amyloid-deposition-in-alzheimer-disease-using-the-radioligand/)
- [Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT](https://scholariq.org/papers/prostate-cancer-molecular-imaging-standardized-evaluation-promise-proposed-mitnm/)
- [Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes](https://scholariq.org/papers/dosimetry-of-sup-177-sup-lu-psma-617-in-metastatic-castration-resistant-prostate/)
- [Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors](https://scholariq.org/papers/appropriate-use-criteria-for-somatostatin-receptor-pet-imaging-in-neuroendocrine/)
- [<sup>68</sup>Ga-DOTATOC Versus <sup>68</sup>Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors](https://scholariq.org/papers/sup-68-sup-ga-dotatoc-versus-sup-68-sup-ga-dotatate-pet-ct-in-functional-imaging/)
- [The Role of <sup>68</sup>Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on <sup>111</sup>In-DTPA-Octreotide Scintigraphy](https://scholariq.org/papers/the-role-of-sup-68-sup-ga-dotatate-pet-in-patients-with-neuroendocrine-tumors/)
- [Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/long-term-follow-up-and-outcomes-of-retreatment-in-an-expanded-50-patient-single/)
- [Imaging of Inflamed and Vulnerable Plaque in Coronary Arteries with <sup>18</sup>F-FDG PET/CT in Patients with Suppression of Myocardial Uptake Using a Low-Carbohydrate, High-Fat Preparation](https://scholariq.org/papers/imaging-of-inflamed-and-vulnerable-plaque-in-coronary-arteries-with-sup-18-sup-f/)
- [Metaanalysis of <sup>68</sup>Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology](https://scholariq.org/papers/metaanalysis-of-sup-68-sup-ga-psma-11-pet-accuracy-for-the-detection-of-prostate/)
- [Assessment of Treatment Response in Patients with Glioblastoma Using <i>O</i>-(2-<sup>18</sup>F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI](https://scholariq.org/papers/assessment-of-treatment-response-in-patients-with-glioblastoma-using-i-o-i-2-sup/)
- [<sup>18</sup>F-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in Osteosarcoma](https://scholariq.org/papers/sup-18-sup-f-fdg-pet-ct-as-an-indicator-of-progression-free-and-overall-survival/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.